Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, United States.
Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, United States.
Front Immunol. 2022 Feb 17;13:843558. doi: 10.3389/fimmu.2022.843558. eCollection 2022.
Microglia have been implicated in many degenerative eye disorders, including retinitis pigmentosa, age-related macular degeneration, glaucoma, diabetic retinopathy, uveitis, and retinal detachment. While the exact roles of microglia in these conditions are still being discovered, evidence from animal models suggests that they can modulate the course of disease. In this review, we highlight current strategies to target microglia in the eye and their potential as treatments for both rare and common ocular disorders. These approaches include depleting microglia with chemicals or radiation, reprogramming microglia using homeostatic signals or other small molecules, and inhibiting the downstream effects of microglia such as by blocking cytokine activity or phagocytosis. Finally, we describe areas of future research needed to fully exploit the therapeutic value of microglia in eye diseases.
小胶质细胞与许多退行性眼病有关,包括色素性视网膜炎、年龄相关性黄斑变性、青光眼、糖尿病性视网膜病变、葡萄膜炎和视网膜脱离。虽然小胶质细胞在这些疾病中的确切作用仍在被发现,但来自动物模型的证据表明,它们可以调节疾病的进程。在这篇综述中,我们强调了目前靶向眼部小胶质细胞的策略及其作为治疗罕见和常见眼部疾病的潜力。这些方法包括用化学物质或辐射清除小胶质细胞、使用体内平衡信号或其他小分子对小胶质细胞进行重编程,以及通过阻断细胞因子活性或吞噬作用来抑制小胶质细胞的下游效应。最后,我们描述了未来需要研究的领域,以充分利用小胶质细胞在眼部疾病中的治疗价值。